KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Treasury Shares (2021 - 2025)

AbCellera Biologics (ABCL) has disclosed Treasury Shares for 5 consecutive years, with $9.0 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Treasury Shares rose 31.5% year-over-year to $9.0 million, compared with a TTM value of $9.0 million through Sep 2025, up 31.5%, and an annual FY2024 reading of $6.6 million, up 62.67% over the prior year.
  • Treasury Shares was $9.0 million for Q3 2025 at AbCellera Biologics, down from $9.4 million in the prior quarter.
  • Across five years, Treasury Shares topped out at $9.7 million in Q1 2025 and bottomed at $184508.0 in Q1 2021.
  • Average Treasury Shares over 5 years is $4.9 million, with a median of $4.4 million recorded in 2023.
  • The sharpest move saw Treasury Shares soared 1511.88% in 2022, then grew 3.26% in 2023.
  • Year by year, Treasury Shares stood at $815744.0 in 2021, then skyrocketed by 383.85% to $3.9 million in 2022, then increased by 3.26% to $4.1 million in 2023, then surged by 62.67% to $6.6 million in 2024, then skyrocketed by 35.82% to $9.0 million in 2025.
  • Business Quant data shows Treasury Shares for ABCL at $9.0 million in Q3 2025, $9.4 million in Q2 2025, and $9.7 million in Q1 2025.